Hosted on MSN45m
RBC Capital Downgrades Intra-Cellular Therapies (ITCI)
Fintel reports that on January 22, 2025, RBC Capital downgraded their outlook for Intra-Cellular Therapies (NasdaqGS:ITCI) ...
RBC Capital Remains a Hold on SAGE Therapeutics (SAGE)
RBC Capital analyst Brian Abrahams maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) on January 21 and set a price target ...
RBC Capital Keeps Their Hold Rating on Incyte (INCY)
RBC Capital analyst Brian Abrahams maintained a Hold rating on Incyte (INCY – Research Report) on January 21 and set a price target of $70.00.
bovnews9h
Why Did RBC Capital Mkts Give CF Industries Holdings, Inc. (CF) Stock Sector Perform Rating?
CF Industries Holdings, Inc. (CF) stock saw a decline, ending the day at $93.66 which represents a decrease of $-3.35 or -3.45% from the prior close of $97.01. The stock opened at $95.5 and touched a ...
Shopify investors may have a chance to buy the dip after earnings - RBC Capital
RBC Capital Markets sized up Shopify Inc. (NYSE:SHOP) ahead of the company's Q4 earnings report due out in a few weeks. Analyst Paul Treiber said data from several third-party sources indicates ...
What’s wrong with the Unilever share price?
The Unilever share price looked like it was about to kick into gear... but it's idling again. Harvey Jones now wonders if his ...
Hochschild Mining Shares Tumble on 2025 Capital Expenditure, Cost Guidance
However, its 2025 costs and capital expenditure guidance exceeded analyst expectations as well as its own previous guidance. For full-year 2025, Hochschild expects capital expenditure between $197 ...